Page 124 - 《中国药房》2021年16期
P. 124

疗的临床分析[J].医药论坛杂志,2015,36(11):38-39.                 immunoglobulin combined with prednisolone following
        [32]  华晓星,李结贞,江莲英.激素治疗在丙种球蛋白无反应                          resistance to initial intravenous immunoglobulin treatment
             性川崎病患儿中的应用效果[J].实用临床医学,2020,21                      of acute Kawasaki disease[J]. J Pediatr,2013,163(2):
             (12):40-42.                                         521-526.
        [33]  郭翼红,俞海国,张雅媛,等.静脉注射用丙种球蛋白联合                    [46]  JIBIKI T,KATO I,SHIOHAMA T,et al. Intravenous im-
             糖皮质激素治疗丙种球蛋白无反应型川崎病[J].儿科药                          mune globulin plus corticosteroids in refractory Kawasaki
             学杂志,2016,22(5):9-11.                                disease[J]. Pediatrics International,2011,53(5):729-735.
        [34]  陈颖,曾嵘.甲基泼尼松治疗静脉丙种球蛋白无反应型川                     [47]  HASHINO K,ISHII M,IEMURA M,et al. Re-treatment
             崎病的疗效观察[J].儿科药学杂志,2016,22(8):17-19.                 for immune globulin-resistant Kawasaki disease:a com-
        [35]  陈鹏,朱之尧,曾晓辉.丙种球蛋白无反应性川崎病的治                          parative study of additional immune globulin and steroid
             疗研究[J].中南药学,2011,9(4):307-309.                      pulse therapy[J]. Pediatr Int,2001,43(3):211-217.
        [36]  WANG Z P,CHEN F Y,WANG Y F,et al. Methylpredni-  [48]  HAMADA H,SUZUKI H,ONOUCH Y,et al. Efficacy of
             solone pulse therapy or additional IVIG for patients with  primary treatment with immunoglobulin plus ciclosporin
             IVIG-resistant Kawasaki disease[J]. J Immunol Res,2020  for prevention of coronary artery abnormalities in patients
             (4):1-7.                                            with Kawasaki disease predicted to be at increased risk of
        [37]  TREMOULET A H,JAIN S,JAGGI P,et al. Infliximab     non-response to intravenous immunoglobulin(KAICA):a
             for intensification of primary therapy for Kawasaki di-  randomised controlled,open-label,blinded-endpoints,
             sease:a phase 3 randomised,double-blind,placebo-con-  phase 3 trial[J]. Lancet,2019,393(10176):1128-1137.
             trolled trial[J]. Lancet,2014,383(9930):1731-1738.  [49]  FURUKAWA T,KISHIRO M,AKIMOTO K,et al. Ef-
        [38]  TERAGUCHI M,OGINO H,YOSHIMURA K,et al. Ste-        fects of steroid pulse therapy on immunoglobulin-resistant
             roid pulse therapy for children with intravenous immuno-  Kawasaki disease[J]. Arch Dis Child,2015,93(2):142-
             globulin therapy-resistant Kawasaki disease:a prospective  146.
             study[J]. Pediatric Cardiology,2012,34(4):959-963.  [50]  BURNS J C,BEST B M,MEJIAS A,et al. Infliximab
        [39]  SON M B,GAUVREAU K,BURNS J C,et al. Infliximab     treatment of intravenous immunoglobulin-resistant Kawa-
             for intravenous immunoglobulin resistance in Kawasaki  saki disease[J]. J Pediatr,2008,153(6):833-838.
             disease:a retrospective study[J]. J Pediatr,2011,158(4):  [51]  花旺,龚方戚.川崎病丙种球蛋白耐药的预测和治疗[J].
             644-649.                                            中国小儿急救医学,2020,27(9):650-653.
        [40]  PORTMAN M A,DAHDAH N S,SLEE A,et al. Etaner-  [52]  王韧健,谢利剑,黄敏.静脉注射丙种球蛋白无反应型川
             cept with IVIG for acute Kawasaki disease:a randomized  崎病治疗进展[J].临床儿科杂志,2016,34(1):68-72.
             controlled trial[J]. Pediatrics,2019,143(6):e20183675.  [53]  MURATA K,MOTOMURA Y,TANAKA T,et al. Calci-
        [41]  OGATA S,OGIHARA Y,HONDA T,et al. Corticosteroid    neurin inhibitors exacerbate coronary arteritis via the
             pulse combination therapy for refractory Kawasaki dis-  MyD88 signalling pathway in a murine model of Kawasa-
             ease:a randomized trial[J]. Pediatrics,2012,129(1):e17-  ki disease[J]. Clin Exp Immunol,2017,190(1):54-67.
             e23.                                           [54]  KAWAMURA Y,KANAI T,TAKESHITA S,et al. Use of
        [42]  MORI M,HARA T,KIKUCHI M,et al. Infliximab versus   the urinary trypsin inhibitor ulinastatin for acute Kawasa-
             intravenous immunoglobulin for refractory Kawasaki dis-  ki disease[J]. Nihon Rinsho,2014,72(9):1650-1653.
             ease:a phase 3,randomized,open-label,active-controlled,  [55]  易跃雄,张蔚,刘小媛,等.网状 Meta 分析图形结果解
             parallel-group,multicenter trial[J]. Sci Rep,2018,8(1):  读[J].中国循证医学杂志,2015,15(1):103-109.
             1994.                                          [56]  CHAN H,CHI H,YOU H,et al. Indirect-comparison me-
        [43]  MIYATA K,KANEKO T,MORIKAWA Y,et al. Efficacy       ta-analysis of treatment options for patients with refracto-
             and safety of intravenous immunoglobulin plus predniso-  ry Kawasaki disease[J]. BMC Pediatrics,2019,19(1):
             lone therapy in patients with Kawasaki disease(post  158.
             RAISE):a multicentre,prospective cohort study[J].  [57]  XUE L J,WU R,DU G L,et al. Effect and Safety of TNF
             Lancet Child Adolesc Health,2018,2(12):855-862.     inhibitors in immunoglobulin-resistant Kawasaki disease:
        [44]  MORI M,HARA T,KIKUCHI M,et al. Effects of methyl-  a meta-analysis[J]. Clin Rev Allergy Immunol,2017,52
             prednisolone pulse on cytokine levels in Kawasaki disease  (3):389-400.
             patients unresponsive to intravenous immunoglobulin[J].      (收稿日期:2021-04-13  修回日期:2021-07-13)
             Eur J Pediatr,2008,167(10):1119-1123.                                               (编辑:陈 宏)
        [45]  KOBAYASHI T,MORIKAWA A. Efficacy of intravenous




        ·2034 ·  China Pharmacy 2021 Vol. 32 No. 16                                 中国药房    2021年第32卷第16期
   119   120   121   122   123   124   125   126   127   128   129